Tian Yuan acts on CanSino Biologics’STAR Market IPO
Tian Yuan Law Firm has advised biotech company CanSino Biologics on its $749 million initial public offering on the Shanghai STAR Market.
Established in 2009, the Tianjin-headquartered CanSino focuses on the research, development, production and selling of innovative vaccines. In March 2019, CanSino launched its IPO in Hong Kong Stock Exchange. With this STAR Market IPO, CanSino has become the first vaccine company to have a dual listing to be listed in both Hong Kong and Shanghai, and also the second pre-revenue biotech company to list in both places after Junshi Biosciences’ STAR Market IPO in this July.
The Tian Yuan team was led by partners Liu Yan, Fu Siqi and Zhen Yueneng. The underwriters of this IPO are CITIC Securities, CICC and Bohai Securities.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.